TRPC6 and Duchenne muscular dystrophy: In conclusion, we identified TRPC6 as a major component of the pathophysiology of DMD — showing that its chronic suppression genetically and, most importantly, using a small-molecule inhibitor improves striated muscle function, improves bone remodeling, lessens muscle fibrosis, and improves survival in one of the most severe DMD mouse models yet generated.